Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$158.30
neg -2.26
-1.41%
Today's Range: 156.38 - 161.92 | AMGN Avg Daily Volume: 3,533,300
Last Update: 04/29/16 - 3:59 PM EDT
Volume: 5,385,141
YTD Performance: -1.09%
Open: $159.39
Previous Close: $160.56
52 Week Range: $130.09 - $181.81
Oustanding Shares: 752,091,038
Market Cap: 121,086,657,118
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 2 2 2 2
Hold 9 9 9 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.30 2.30 2.30 2.25
Latest Dividend: 1.00
Latest Dividend Yield: 2.48%
Dividend Ex-Date: 05/13/16
Price Earnings Ratio: 17.77
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
17.77 17.80 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
8.23% -1.19% 48.15%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.00 0.20 0.08
Net Income 34.50 0.60 0.17
EPS 35.20 0.60 0.18
Earnings for AMGN:
EBITDA 10.63B
Revenue 21.66B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $2.72 $2.78 $10.82 $11.85
Number of Analysts 9 9 12 9
High Estimate $2.83 $3.08 $11.70 $12.80
Low Estimate $2.62 $2.67 $10.53 $11.35
Prior Year $2.57 $2.72 $10.38 $10.82
Growth Rate (Year over Year) 5.71% 2.29% 4.20% 9.59%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
This earnings season continues to disappoint, and technology names are leading the downward charge.

Some Stocks Are Really Cheap Real Money Pro($)

There are lots of winners in the first quarter.
It's important to focus on hitting singles in this overbought and earnings-starved environment.
This will still be fourth quarter in a row that profits have declined year over year.
In this choppy market, the sweet spot is large-caps with these three core attributes.
It has multiple layers of resistance to work through to maintain a new bull leg.  
And yet, Endocyte has a deep pipeline.
It's better to broaden your exposure to avoid seeing your portfolio suffer.
I am starting to get more confident that the small caps are ready to bounce.

Columnist Conversations

Up in an hour or so! Enjoy your weekend and thanks for reading my Diary.
HIG
HIG, the object of my affection today, rips +$0.50 higher in the last few minutes of trading. Just wishing and...
Rolling SDS long sale proceeds into SPY/QQQ $2.5 billion to buy at month end, aiding markets. Trying to be opp...
Money Management firm Waddell & Reed (WDR) is having a bad year. The news is reflected in the price which ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.